Overview of pharmacogenomic testing in clinical practice.

ABSTRACT:

Introduction

Pharmacogenomic tests relevant to neuropsychiatric medications have been clinically available for more than a decade, but the utility of regular testing is still unknown. Tests available include both pharmacokinetic and pharmacodynamic targets. The potential practice benefits vary with each target.

Methods

A 10-year literature review was completed utilizing the PubMed database to identify articles relating to the specific pharmacogenomic targets discussed. Further article selection was based on author review for clinical utility.

Results

The clinical dosing guidance available for neuropsychiatric medications such as selective serotonin reuptake inhibitors and tricyclic antidepressants with varying genotypes is useful and has strong evidence to support tes

SUBMITTER: Gross T 

PROVIDER: S-EPMC6125117 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature